Latham-Led Novan Files $60M IPO To Boost Acne Drug
Late-stage pharmaceutical company Novan Inc. filed plans on Wednesday for a $60 million initial public offering to help fund the development of its dermatological treatments, with guidance from Latham & Watkins...To view the full article, register now.
Already a subscriber? Click here to view full article